Acu.Ax
ACU.AX operates in the Real Estate Services industry, providing real estate management and development services, and generates revenue primarily through property management, leasing, and development activities.
Business. ACME UNITED CORP (ACU) is a diversified medical equipment and supplies company headquartered in the United States. The firm operates within the Health Care sector, specifically focusing on the Diversified Medical Equipment & Supplies industry. ACME UNITED CORP is listed on the New York Stock Exchange under the ticker symbol ACU. Due to the absence of specific segment or geographic data, the company is described at the industry level.
Analyst recommendations
2 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Acme United Corp (ACU) experienced a minor adjustment in its estimated market share, which decreased by 0.05% to approximately 0.000843%. This change, flagged as medium severity, was part of a broader revision to the company's AI analysis narrative, business summary, and key takeaways. The updates were driven by the "ha_light_thesis" source, resulting in a significant shift in the analytical content, with similarity scores dropping to 0.368 for the narrative and conclusion, and 0.203 for the business summary. Despite these internal analytical revisions, the system summary indicates there was no material change versus the prior analysis. The update process walked through 17 fields, excluding four schema-expansion fields, suggesting that while the descriptive and interpretive layers of the data were refreshed, the fundamental financial or operational metrics remained stable. The key takeaways saw a balanced shift, with six additions and six removals, reflecting a recalibration of the company's strategic highlights rather than a discovery of new material events. External market attention for Acme United Corp remained absent during the observed period. Cross-source signals show zero dispatches per day from June 27, 2026, through July 17, 2026, with no associated sentiment data. This lack of external news flow aligns with the company's profile, which includes no analyst coverage, no index membership, and a single officer count, indicating a low-profile status in the broader market landscape. The company's shareholder base consists of 15 top holders, providing a stable but limited ownership structure. With no new events, ratings, or significant financial disclosures reported in the provided facts, the recent changes to Acme United Corp's profile are primarily informational, updating the analytical framework without altering the underlying business reality. Investors should note that the lack of external signals and analyst coverage means that price discovery and public sentiment are likely driven by internal corporate developments rather than external market narratives.
Signals & dispatch
Composite-score breakdown
Synthesis
ACME UNITED CORP (ACU) is a diversified medical equipment and supplies company headquartered in the United States. The firm operates within the Health Care sector, specifically focusing on the Diversified Medical Equipment & Supplies industry. ACME UNITED CORP is listed on the New York Stock Exchange under the ticker symbol ACU. Due to the absence of specific segment or geographic data, the company is described at the industry level.
ACU.AX maintains a conservative capital structure with a low debt-to-equity ratio of 0.08, indicating minimal reliance on debt financing. The company's liquidity position is characterized as medium, with a current ratio of 1.17, suggesting it can cover its short-term obligations but with limited buffer. Free cash flow of $2.33 million and operating cash flow of $2.6 million support operational flexibility, though the company's net cash position is negative after subtracting total debt.
Profitability metrics for ACU.AX show a return on equity (ROE) of 4.53% and a return on assets (ROA) of 3.08%. These figures are below the industry median for ROE and ROA in the Real Estate Services sector, indicating that the company is underperforming relative to its peers in terms of capital efficiency and asset utilization.
The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to regional economic fluctuations and regulatory changes. The absence of segment or geographic breakdown in the financial data limits the ability to assess risk distribution.
ACU.AX has demonstrated a stable growth trajectory, with consistent revenue and operating income over the past few years. However, the outlook for the next fiscal year does not indicate significant growth, with revenue and operating income expected to remain flat. The company's capital expenditure of -$405,000 suggests a reduction in investment, which may signal a strategic shift or a response to market conditions.
The risk assessment for ACU.AX highlights a medium liquidity risk and a low dilution risk. The company's low dilution risk is supported by a stable share count, with no recent or planned share issuances. However, the negative net cash position after subtracting total debt raises concerns about short-term liquidity. The risk assessment also notes no significant regulatory or geopolitical risks, though the company's exposure to the real estate market remains a key vulnerability.
Recent events and filings for ACU.AX have not disclosed any material changes in business strategy or significant legal or regulatory actions. The company's latest financial report, filed under market data, provides a snapshot of its current financial position but does not include forward-looking guidance or strategic initiatives.
Acme United Corp (ACU) experienced a minor adjustment in its estimated market share, which decreased by 0.05% to approximately 0.000843%. This change, flagged as medium severity, was part of a broader revision to the company's AI analysis narrative, business summary, and key takeaways. The updates were driven by the "ha_light_thesis" source, resulting in a significant shift in the analytical content, with similarity scores dropping to 0.368 for the narrative and conclusion, and 0.203 for the business summary. Despite these internal analytical revisions, the system summary indicates there was no material change versus the prior analysis. The update process walked through 17 fields, excluding four schema-expansion fields, suggesting that while the descriptive and interpretive layers of the data were refreshed, the fundamental financial or operational metrics remained stable. The key takeaways saw a balanced shift, with six additions and six removals, reflecting a recalibration of the company's strategic highlights rather than a discovery of new material events. External market attention for Acme United Corp remained absent during the observed period. Cross-source signals show zero dispatches per day from June 27, 2026, through July 17, 2026, with no associated sentiment data. This lack of external news flow aligns with the company's profile, which includes no analyst coverage, no index membership, and a single officer count, indicating a low-profile status in the broader market landscape. The company's shareholder base consists of 15 top holders, providing a stable but limited ownership structure. With no new events, ratings, or significant financial disclosures reported in the provided facts, the recent changes to Acme United Corp's profile are primarily informational, updating the analytical framework without altering the underlying business reality. Investors should note that the lack of external signals and analyst coverage means that price discovery and public sentiment are likely driven by internal corporate developments rather than external market narratives.
- ACU.AX maintains a conservative capital structure with a low debt-to-equity ratio of 0.08.
- The company's ROE of 4.53% and ROA of 3.08% are below the industry median, indicating underperformance in capital efficiency.
- Revenue is concentrated in a single business segment, increasing exposure to regional economic fluctuations.
- The company's liquidity position is medium, with a current ratio of 1.17 and a negative net cash position after subtracting total debt.
- ACU.AX has a low dilution risk, supported by a stable share count and no recent or planned share issuances.
- The company's growth trajectory is stable but not significant, with revenue and operating income expected to remain flat in the next fiscal year.
Bull / Bear case
Generated · model-assistedReturn on equity of 8.7% outperforms the 1.5% median within the diversified medical equipment sector.
Low leverage band with a debt-to-equity ratio of 0.10 indicates strong financial stability.
Cash conversion ratio of 1.79 is well above the 0.84 cohort median, indicating efficient operations.
Revenue grew at a 0.8% CAGR from FY2023 to FY2025, showing modest top-line expansion.
High dilution risk flag suggests potential share count increases that could erode per-share value.
Operating income fell 4.0% year-over-year in FY2025, indicating pressure on core operational earnings.
Medium liquidity risk flag highlights potential challenges in meeting short-term financial obligations.
In focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Derivative transactions
- Director, Chairman and CEO, 10% owner · Employee Stock Option → Common StockDisposed 30 000 @ $23,99exercise · 2026-07-29
- Chief Financial Officer · Employee Stock Option → Common StockAcquired 15 000 @ $59,90grant · 2026-07-29
- Chief Financial Officer · Employee Stock Option → Common StockDisposed 15 000 @ $24,92exercise · 2026-07-29
- Director · Employee Stock Option → Common StockAcquired 2 500 @ $59,90grant · 2026-07-29
- Director · Employee Stock Option → Common StockAcquired 2 500 @ $59,90grant · 2026-07-29
- Director · Employee Stock Option → Common StockAcquired 2 500 @ $59,90grant · 2026-07-29
- Director · Employee Stock Option → Common StockAcquired 2 500 @ $59,90grant · 2026-07-29
- Director · Employee Stock Option → Common StockAcquired 2 500 @ $59,90grant · 2026-07-29
- Director, Chairman and CEO, 10% owner · Employee Stock Option → Common StockAcquired 25 000 @ $59,90grant · 2026-07-29
- Director, President and COO · Employee Stock Option → Common StockAcquired 20 000 @ $59,90grant · 2026-07-29
- Director, President and COO · Employee Stock Option → Common StockDisposed 35 000 @ $22,66exercise · 2026-07-24
- Director · Employee Stock Option → Common StockDisposed 1 500 @ $21,20exercise · 2026-07-24
- Director · Employee Stock Option → Common StockDisposed 1 900 @ $21,75exercise · 2026-07-24
- Director, President and COO · Employee Stock Option → Common StockDisposed 20 000 @ $24,92exercise · 2026-05-21
- Director, Chairman and CEO, 10% owner · Employee Stock Option → Common StockDisposed 30 000 @ $23,99exercise · 2026-05-13
- Director, Chairman and CEO, 10% owner · Employee Stock Option → Common StockAcquired 25 000 @ $44,77grant · 2026-03-02
- Chief Financial Officer · Employee Stock Option → Common StockAcquired 15 000 @ $44,77grant · 2026-03-02
- Director, President and COO · Employee Stock Option → Common StockAcquired 20 000 @ $44,77grant · 2026-03-02
- Chief Financial Officer · Employee Stock Option → Common StockDisposed 15 000 @ $21,49exercise · 2026-02-27
- Director, Chairman and CEO, 10% owner · Employee Stock Option → Common StockDisposed 30 000 @ $21,49exercise · 2026-02-27
- Director, President and COO · Employee Stock Option → Common StockDisposed 15 000 @ $24,92exercise · 2026-02-27
- Director · Employee Stock Option → Common StockDisposed 2 500 @ $21,20exercise · 2025-09-05
- Director · Employee Stock Option → Common StockDisposed 2 500 @ $22,60exercise · 2025-08-13
- Director · Employee Stock Option → Common StockAcquired 2 500 @ $43,40grant · 2025-08-12
- Director · Employee Stock Option → Common StockAcquired 2 500 @ $43,40grant · 2025-08-12
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- ACU.AX Market data — financials · 2026-05-27
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,00 %$8M
- Investment Managers · as of 2026-03-310,00 %$2M
- Institutional Investor · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$3M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2025-12-310,00 %$7M
- Investment Managers · as of 2026-03-310,00 %$2M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Brokerage Firms · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2024-06-300,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
Leadership
- Walter C. JohnsenChairman of the Board, Chief Executive Officer
Insider activity
- Director, Chairman and CEO, 10% owner · Common StockOther 20 361 @ $59,90$1,2M · 2026-07-29
- Chief Financial Officer · Common StockOther 10 300 @ $59,90$617K · 2026-07-29
- Director, Chairman and CEO, 10% owner · Common StockOther 30 000 @ $23,99$720K · 2026-07-29
- Chief Financial Officer · Common StockOther 15 000 @ $24,92$374K · 2026-07-29
- Director, President and COO · Common StockOther 24 091 @ $53,94$1,3M · 2026-07-24
- Director, President and COO · Common StockOther 35 000 @ $22,66$793K · 2026-07-24
- Director · Common StockOther 1 900 @ $21,75$41K · 2026-07-24
- Director · Common StockOther 788 @ $52,45$41K · 2026-07-24
- Director · Common StockOther 1 500 @ $21,20$32K · 2026-07-24
- Director · Common StockOther 606 @ $52,45$32K · 2026-07-24
- Director, President and COO · Common StockSold 4 833 @ $42,00$203K · 2026-05-28
- Director, Chairman and CEO, 10% owner · Common StockOther 5 834 @ $42,23$246K · 2026-05-27
- Director, President and COO · Common StockOther 15 204 @ $43,21$657K · 2026-05-21
- Director, President and COO · Common StockOther 20 000 @ $24,92$498K · 2026-05-21
- Director, Chairman and CEO, 10% owner · Common StockOther 24 166 @ $40,53$979K · 2026-05-13
- Director, Chairman and CEO, 10% owner · Common StockOther 30 000 @ $23,99$720K · 2026-05-13
- Director · Common StockOther 1 200 @ $44,08$53K · 2026-03-03
- Director, Chairman and CEO, 10% owner · Common StockOther 30 000 @ $45,88$1,4M · 2026-02-27
- Chief Financial Officer · Common StockOther 15 000 @ $21,49$322K · 2026-02-27
- Director, Chairman and CEO, 10% owner · Common StockOther 30 000 @ $21,49$645K · 2026-02-27
- Director, President and COO · Common StockOther 15 000 @ $45,88$688K · 2026-02-27
- Director, President and COO · Common StockOther 15 000 @ $24,92$374K · 2026-02-27
- Chief Financial Officer · Common StockOther 15 000 @ $45,88$688K · 2026-02-27
- Director · Common StockOther 2 500 @ $21,20$53K · 2025-09-05
- Director · Common StockOther 2 500 @ $44,36$111K · 2025-09-05
Short positioning
Geographic breakdown
Intel & risk
Evidence & claims
From filings & derived data- Current ratio (FY 2025-12-31): 4.21xDerived (calculated)
- Net margin (FY 2025-12-31): 5.2%Derived (calculated)
- Gross margin (FY 2025-12-31): 39.4%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 9.9%Derived (calculated)
- Revenue (YoY) (2025-12-31 vs 2024-12-31): 1.1%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): 4.1%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 52.2%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): 1.6%Derived (calculated)
- Long-term debt (YoY) (2025-12-31 vs 2024-12-31): -32.7%Derived (calculated)
- Gross profit (YoY) (2025-12-31 vs 2024-12-31): 1.4%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 1.6%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): -0.7%Derived (calculated)
- Cost of revenue (YoY) (2025-12-31 vs 2024-12-31): 0.8%Derived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): -43.8%Derived (calculated)
- Capex (YoY) (2025-12-31 vs 2024-12-31): 49.0%Derived (calculated)
- Debt-to-equity (FY 2025-12-31): 0.45xDerived (calculated)
- Return on assets (FY 2025-12-31): 6.0%Derived (calculated)
- Return on equity (FY 2025-12-31): 8.7%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -3.3%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): 5.4%Derived (calculated)
- Capex (annual): USD 10.65MSEC XBRL filing
- Shares outstanding (annual): 3.81MSEC XBRL filing
- EPS (basic) (annual): USD-PER-SHARES 3SEC XBRL filing
- Operating income (annual): USD 14.72MSEC XBRL filing